Patient Square Capital LP Sells 13,500 Shares of argenex SE $ARGX

Patient Square Capital LP reduced its position in argenex SE (NASDAQ:ARGX) by 46.6% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 15,500 shares of the company’s stock after selling 13,500 shares during the period. argenex makes up 3.1% of Patient Square Capital LP’s investment portfolio, making the stock its 6th largest holding. Patient Square Capital LP’s holdings in argenex were worth $11,432,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. lifted its position in argenex by 91.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,828 shares of the company’s stock valued at $6,511,000 after acquiring an additional 4,217 shares in the last quarter. Allianz Asset Management GmbH increased its holdings in argenex by 21.3% during the 3rd quarter. Allianz Asset Management GmbH now owns 3,671 shares of the company’s stock worth $2,708,000 after purchasing an additional 645 shares in the last quarter. Allspring Global Investments Holdings LLC increased its holdings in argenex by 14.2% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 211,330 shares of the company’s stock worth $162,160,000 after purchasing an additional 26,343 shares in the last quarter. Alta Wealth Advisors LLC purchased a new stake in shares of argenex in the third quarter worth approximately $623,000. Finally, Voya Investment Management LLC lifted its holdings in shares of argenex by 36.3% in the third quarter. Voya Investment Management LLC now owns 21,610 shares of the company’s stock valued at $15,939,000 after purchasing an additional 5,755 shares in the last quarter. Institutional investors own 60.32% of the company’s stock.

argenex Stock Down 0.3%

Shares of ARGX stock opened at $844.41 on Monday. The firm has a market cap of $52.25 billion, a P/E ratio of 36.26, a PEG ratio of 0.73 and a beta of 0.37. The company has a 50 day moving average of $831.22 and a 200-day moving average of $807.73. argenex SE has a 12-month low of $510.05 and a 12-month high of $934.62.

Analysts Set New Price Targets

ARGX has been the subject of several recent research reports. Zacks Research downgraded argenex from a “hold” rating to a “strong sell” rating in a report on Thursday, January 22nd. Weiss Ratings reiterated a “hold (c)” rating on shares of argenex in a report on Wednesday, January 21st. Wall Street Zen lowered shares of argenex from a “buy” rating to a “hold” rating in a research report on Sunday, February 8th. Morgan Stanley boosted their price target on shares of argenex from $1,070.00 to $1,110.00 and gave the stock an “overweight” rating in a report on Thursday, December 4th. Finally, Stifel Nicolaus upped their price objective on shares of argenex from $1,028.00 to $1,248.00 and gave the stock a “buy” rating in a research report on Thursday, December 11th. One research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, argenex has a consensus rating of “Moderate Buy” and a consensus price target of $986.78.

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.